Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: A pilot double-blind randomized trial [ISRCTN45683816]

BMC Complementary and Alternative Medicine

Farahnaz Khalighi-Cigaroudi²  Amir-Hossein Jamshidi²  Khosro Afkham¹  Hasan Fallah-Pour¹  Shahin Akhondzadeh¹ 

[1] Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13185, Iran;Facuty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Others  :  1234315
DOI  :  10.1186/1472-6882-4-12

 received in 2004-04-23, accepted in 2004-09-02,  发布年份 2004

【 摘 要 】

Background

The morbidity and mortality associated with depression are considerable and continue to increase. Depression currently ranks fourth among the major causes of disability worldwide, after lower respiratory infections, prenatal conditions, and HIV/AIDS. Crocus sativus L. is used to treat depression. Many medicinal plants textbooks refer to this indication whereas there is no evidence-based document. Our objective was to compare the efficacy of stigmas of Crocus sativus (saffron) with imipramine in the treatment of mild to moderate depression in a 6-week pilot double-blind randomized trial.

Methods

Thirty adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders, 4^th edition for major depression based on the structured clinical interview for DSM IV participated in the trial. Patients have a baseline Hamilton Rating Scale for Depression score of at least 18. In this double-blind, single-center trial, patients were randomly assigned to receive capsule of saffron 30 mg/day (TDS) (Group 1) and capsule of imipramine 100 mg/day (TDS) (Group 2) for a 6-week study.

Results

Saffron at this dose was found to be effective similar to imipramine in the treatment of mild to moderate depression (F = 2.91, d.f. = 1, P = 0.09). In the imipramine group anticholinergic effects such as dry mouth and also sedation were observed more often that was predictable.

Conclusion

The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression. To the best of our knowledge this is the first clinical trial that supports this indication for saffron. A large-scale trial with placebo control is warranted.

【 授权许可】

   
2004 Akhondzadeh et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Judd L: Mood disorders in the general population represent an important and worldwide public health problem. Int J Clin Psychopharm 1995, 10(suppl 4):5-10.
• [2]Richelson E: Pharmacology of antidepressants-characteristic of the ideal drug. Mayo Clin Proc 1994, 69:1069-1081.
• [3]Demyttenaere K: Compliance during treatment with antidepressants. J Affec Dis 1997, 43:27-39.
• [4]Donoghue JM, Tylee A: The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996, 168:164-168.
• [5]MacDonald TM: Treatment of depression: prescription for success? Prim Care Psychiatry 1997, 3(suppl 1):7-10.
• [6]Ernst E: St. John's wort, an anti-depressant? A systematic, criteria based review. Phytomedicine 1995, 2:67-71.
• [7]De Smet PAGM, Nolen WA: St. John's wort as an antidepressant. BMJ 1996, 313:241-242.
• [8]Rios JL, Recio MC, Giner RM, Manez S: An update review of saffron and its active constituents. Phtother Res 1996, 10:189-193.
• [9]Karimi G, Hosseinzadeh H, Khaleghpanah P: Study of antidepressant effect of aqueous and ethanolic of Crocus sativus in mice. Iranian J Basic Med Sci 2001, 4:11-15.
• [10]Hosseinzadeh H, Younesi H: Petal and stigma extracts of Crocus sativus L. have antinociceptive and anti-inflammatory effects in mice. BMC Pharmacol 2002, 2:7. BioMed Central Full Text
• [11]Addullaev FI: Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med 2002, 227:20-25.
• [12]Abe K, Saito H: Effects of saffron and its constituent crocin on learning behavior and long-term potentiation. Phytother Res 2000, 14:149-52.
• [13]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV). American Psychiatric Association, Washington, D.C 4th edition. 1994.
• [14]Hamilton M: A rating scale for depression. J Neurol Neurosurg 1960, 3:62-66.